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BACKGROUND
Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically hetero-
geneous. Gene-expression profiling has identified subgroups of DLBCL (activated 
B-cell–like [ABC], germinal-center B-cell–like [GCB], and unclassified) according 
to cell of origin that are associated with a differential response to chemotherapy 
and targeted agents. We sought to extend these findings by identifying genetic 
subtypes of DLBCL based on shared genomic abnormalities and to uncover thera-
peutic vulnerabilities based on tumor genetics.
METHODS
We studied 574 DLBCL biopsy samples using exome and transcriptome sequenc-
ing, array-based DNA copy-number analysis, and targeted amplicon resequencing 
of 372 genes to identify genes with recurrent aberrations. We developed and imple-
mented an algorithm to discover genetic subtypes based on the co-occurrence of 
genetic alterations.
RESULTS
We identified four prominent genetic subtypes in DLBCL, termed MCD (based on 
the co-occurrence of MYD88L265P and CD79B mutations), BN2 (based on BCL6 fusions 
and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on 
EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes 
distinguished each genetic subtype from other DLBCLs. These subtypes differed 
phenotypically, as judged by differences in gene-expression signatures and re-
sponses to immunochemotherapy, with favorable survival in the BN2 and EZB 
subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic 
pathways suggested that MCD and BN2 DLBCLs rely on “chronic active” B-cell 
receptor signaling that is amenable to therapeutic inhibition.
CONCLUSIONS
We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and 
clinical characteristics, providing a potential nosology for precision-medicine 
strategies in DLBCL. (Funded by the Intramural Research Program of the National 
Institutes of Health and others.)
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Gene-expression profiling defined the activated B-cell–like (ABC) and ger-minal-center B-cell–like (GCB) subgroups 
of diffuse large B-cell lymphoma (DLBCL), leav-
ing approximately 10 to 20% of cases “unclassi-
fied.”1,2 This phenotypic distinction is associated 
with overall survival after standard therapy with 
rituximab, cyclophosphamide, doxorubicin, vin-
cristine, and prednisone (R-CHOP) chemother-
apy3 and predicts response of relapsed or refrac-
tory DLBCL to ibrutinib, an inhibitor of B-cell 
receptor–dependent nuclear factor κB (NF-κB) 
activation.4 Responses to ibrutinib were especially 
frequent in ABC tumors that have both a muta-
tion in CD79B, encoding a B-cell receptor sub-
unit, and the MYD88L265P mutation — a finding 
that suggests that tumor genotype could influ-
ence response.
Genomic sequencing studies in DLBCL have 
focused on recurrent mutations in individual 
genes, revealing oncogenic mechanisms (reviewed 
by Shaffer et al.5). Functional genomic screening 
has provided a complementary view of regula-
tory pathways that are essential for the prolif-
eration and survival of DLBCL cells.6-8 Here, we 
undertook a multiplatform analysis of structural 
genomic abnormalities and gene expression in 
DLBCL biopsy samples. We hypothesized that 
this hybrid approach might yield a nosology of 
DLBCL based on shared genetic pathogenesis 
that could aid in our understanding of treatment 
response and identify therapeutic vulnerabilities.
Me thods
Procedures
Fresh-frozen DLBCL biopsy samples were ana-
lyzed by means of exome and transcriptome se-
quencing, deep amplicon resequencing of 372 
genes, and DNA copy-number analysis (Fig. S1A 
in Supplementary Appendix 1, available with the 
full text of this article at NEJM.org). Most biop-
sies were performed before treatment (96.5%), 
and the biopsy samples included ABC cases 
(51.4%), GCB cases (28.6%), and unclassified 
cases (20.0%). Because most biopsy samples 
lacked matched normal DNA, we developed a 
tumor-only mutation-calling pipeline. Using se-
quencing data from 48 cases with matched nor-
mal DNA, we created and validated a random 
forest-based model of somatic mutations, which 
predicted that 94% of the mutations called by 
our tumor-only pipeline are somatic (see the 
Methods section in Supplementary Appendix 1).
Statistical Analysis
P values relating discrete variables to each other 
were calculated with the use of a Fisher’s exact 
test. P values for survival were calculated from a 
Cox proportional-hazards score test. The score 
on the International Prognostic Index (IPI; range, 
0 to 5, with higher scores indicating greater 
risk) was treated as a categorical variable: low 
(score of 0 or 1), intermediate (score of 2 or 3), 
or high (score of 4 or 5). P values for the differ-
ences in signature averages between DLBCL ge-
netic subtypes were derived from Student t-tests. 
All P values reported are two-sided.
R esult s
Genetic Distinctions among Gene-Expression 
Subgroups
Multiplatform genomic analysis of 574 DLBCL 
biopsy samples identified genes that were altered 
at significantly different frequencies (P<0.01) in 
ABC and GCB cases (Fig. 1A; and Fig. S1B in 
Supplementary Appendix 1 and Tables S1 through 
S8 in Supplementary Appendix 2, available at 
NEJM.org). Because the genetic composition of 
unclassified DLBCL is unknown, we enriched for 
these cases (20.0% in our cohort, as compared 
with 11.3% in a population-based cohort9). 
Among common genetic features in unclassified 
DLBCL, NOTCH2 mutations and BCL6 fusions 
significantly co-occurred (P = 2.78×10−12) and dis-
tinguished unclassified from other DLBCLs 
(Fig. 1B, and Fig. S1C and S1D in Supplementary 
Appendix 1). Unclassified cases were enriched 
for mutations targeting SPEN, an inhibitor of 
NOTCH-dependent gene expression, and 30.4% 
of cases had NOTCH2 or SPEN mutations (Fig. 1B, 
and Fig. S1C in Supplementary Appendix 1). We 
additionally identified gain-of-function NOTCH1 
mutations in 19 cases (Fig. S1C in Supplemen-
tary Appendix 1). However, these were primarily 
in ABC cases (95%) and never co-occurred with 
NOTCH2 or SPEN mutations, which suggests that 
NOTCH1 and NOTCH2 contribute to distinct 
pathogenetic pathways.
We next investigated whether genetic aberra-
tions were correlated with the ABC–GCB predic-
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tor score, a quantitative gene-expression metric 
with low values for the most GCB-like cases and 
high values for the most ABC-like (Fig. 1C). 
NOTCH2 mutations and BCL6 fusions were con-
centrated in the center of this distribution, a 
finding consistent with their enrichment in un-
classified DLBCL. In contrast, cases with CD79B 
and MYD88L265P mutations were enriched at the 
far ABC end of the spectrum, with significant co-
occurrence of these abnormalities (P = 2.81×10−11) 
(Fig. 1C). Although most NOTCH1 mutant cases 
were ABC DLBCL, none had CD79B or MYD88L265P 
mutations and their predictor scores were signifi-
cantly lower than those of the CD79B–MYD88L265P 
double-mutant cases (P = 0.006) (Fig. 1C). On the 
GCB end of the spectrum, EZH2 mutations and 
BCL2 translocations significantly co-occurred 
(P = 6.39×10−14) and were present in cases with 
the lowest predictor scores (Fig. 1C). Together, 
these analyses suggest that the gene-expression 
subgroups may have distinct genetic subtypes.
A Genetic Classifier for DLBCL
To identify genetic subtypes in DLBCL, we created 
an automated method that starts with a set of 
seed classes and iteratively moves cases into and 
out of the classes to optimize a genetic distinc-
tiveness metric (see the Methods section and 
Fig. S2 in Supplementary Appendix 1). We chose 
four seeds as follows: CD79B–MYD88L265P double 
mutation, NOTCH2 mutation or BCL6 fusion in 
ABC or unclassified DLBCL, NOTCH1 mutation, 
and EZH2 mutation or BCL2 translocation. The 
algorithm converged on genetic subtypes that 
we term MCD (71 cases, from the MYD88L265P–
CD79B seed), BN2 (98 cases, from the BCL6–
NOTCH2 seed), N1 (19 cases, from the NOTCH1 
seed), and EZB (69 cases, from the EZH2–BCL2 
seed). A separate algorithm that used random for-
est methods produced significantly overlapping 
genetic subtypes (P<1×10−105) (see the Methods 
section in Supplementary Appendix 1). Among 
non-subtyped “other” cases, the only gene that 
was mutated in more than 10% of cases and was 
significantly enriched in this subset was TET2 
(10.5% prevalence, P = 0.03). Thus, additional ge-
netic subtypes were not apparent in our data set 
but may emerge from the study of larger DLBCL 
cohorts.
The MCD and N1 subtypes were dominated 
by ABC cases, EZB included mostly GCB cases, 
and BN2 had contributions from all three gene-
expression subgroups (Fig. 2A). Overall, we clas-
sified 44.8% of our samples into these geneti-
cally “pure” subtypes of DLBCL and recognize 
that non-subtyped cases may share genetic fea-
tures as well as etiologic factors with the ge-
netic subtypes (Fig. 2B). Because we deliberately 
skewed our sample cohort toward ABC and un-
classified cases, we modeled the expected prev-
alence of the genetic subtypes using a recent 
population-based analysis of the prevalence of 
ABC, GCB, and unclassified DLBCL.9 On the 
basis of the gene-expression predictor classifica-
tions of MCD, BN2, N1, and EZB cases, we esti-
mate that these genetic subtypes would com-
prise 46.6% of cases (Fig. 2C).
To explore how this subtype classification 
might be implemented clinically, we created a 
subtype predictor using mutations in 50 genes 
and translocations of BCL2 and BCL6 (see the 
Methods section in Supplementary Appendix 1). 
In 10-fold cross-validation testing, the predictor 
was 94.8% accurate. A related predictor that in-
cluded amplifications and homozygous deletions 
achieved 97.5% accuracy. Thus, next-generation 
sequencing tests for this subtype distinction 
would be feasible.
Figure 1 (facing page). Relationship between Gene- 
Expression Subgroups and Genetic Alterations.
Panel A shows genetic aberrations that distinguish the 
activated B‑cell–like (ABC) and germinal‑center B‑cell–
like (GCB) subgroups of diffuse large B‑cell lymphoma 
(DLBCL). Shown is the prevalence of the indicated ge‑
netic abnormalities in 72 genes in ABC and GCB, along 
with the log10 P value for the difference in prevalence 
between the two subgroups. Putative assignment as an 
oncogene (Onc), tumor suppressor (TS), or target of 
aberrant somatic hypermutation (SHM) is shown. Amp 
denotes amplification, Fus gene fusion, Gain single‑copy 
gain, HD homozygous deletion, HL heterozygous loss, 
Mut mutation, Transloc translocation, and Trunc protein‑
truncating mutation. Panel B shows genetic lesions that 
are associated with unclassified DLBCL. Shown is the 
prevalence of the indicated genetic aberrations in the 
gene‑expression subgroups, along with the log10 P val‑
ues for the differences between unclassified and either 
ABC or GCB. Panel C shows the correlation between 
genetic abnormalities and the ABC–GCB gene‑expres‑
sion predictor score. The ABC–GCB predictor score is a 
quantitative metric used to assign DLBCL cases to the 
indicated gene‑expression subgroups. High values (blue) 
are on the ABC end of the spectrum, and low values 
(yellow) are on the GCB end of the spectrum. The log10 
P value of the correlation between the predictor score 
and the presence of the indicated aberrations is shown.
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A total of 79 genes with aberrations that 
characterized each genetic subtype are shown in 
Figure S2B in Supplementary Appendix 1. 
MYD88L265P or a CD79B aberration (mutation or 
amplification) was present in 82% of MCD cases, 
with 42% bearing both abnormalities. MCD had 
frequent gain or amplification of SPIB, encoding 
a transcription factor that, with IRF4, defines 
the ABC phenotype and promotes plasmacytic 
differentiation.10 Full plasmacytic differentiation 
is blocked in MCD by mutations that inactivate 
BLIMP1 (PRDM1).11,12 Known tumor suppressors 
in MCD include CDKN2A, ETV6, BTG1, and BTG2, 
and putative tumor suppressors include TOX, 
SETD1B, FOXC1, TBL1XR1, and KLHL14. The tumor 
suppressor TP53 was mutated significantly less 
often in MCD than in other subtypes. Immune 
editing appears prominent in MCD genomes, 
with 76% acquiring a mutation or deletion of 
HLA-A, HLA-B, or HLA-C and 30% acquiring trun-
cating mutations targeting CD58, an activator of 
natural killer cells.13
BN2 was dominated by NOTCH pathway ab-
errations, with 73% acquiring a NOTCH2 muta-
tion or amplification, SPEN mutation, or muta-
tion in DTX1, a NOTCH target gene. Many SPEN 
mutant BN2 cases (50%) lacked NOTCH2 aber-
rations, which suggests that NOTCH2 ligand–
induced signaling may play a role in BN2. BCL6 
fusion, the other BN2 hallmark, occurred in 73% 
of cases. BCL6 fusions were enriched in cases 
with NOTCH2, SPEN, or DTX1 lesions to a signifi-
cantly greater extent in BN2 than in non-BN2 
cases (72% vs. 15%, P = 2.31×10−10), a finding that 
suggests oncogenic cooperation between these 
pathways in BN2.
Genetic aberrations targeting regulators of the 
NF-κB pathway were a prominent feature of BN2. 
Lesions targeting the NF-κB negative regulator 
A20 (TNFAIP3) or its partner TNIP1 were com-
mon (55%). Two components of the B-cell recep-
tor–dependent NF-κB pathway, protein kinase C 
beta (PRKCB) and BCL10, were altered by muta-
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Figure 2. Genetic Aberrations That Distinguish Genetic 
Subtypes of DLBCL.
Panel A shows the distribution of gene‑expression sub‑
groups within genetic subtypes, termed MCD (based 
on the co‑occurrence of MYD88L265P and CD79B muta‑
tions), BN2 (based on BCL6 fusions and NOTCH2 mu‑
tations), N1 (based on NOTCH1 mutations), and EZB 
(based on EZH2 mutations and BCL2 translocations). 
Panel B shows the distribution of genetic subtypes 
within gene‑expression subgroups. In Panels A and B, 
the number of cases of DLBCL is shown in parenthe‑
ses. Panel C shows the predicted prevalence of the in‑
dicated DLBCL subsets in a population‑based cohort.9
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tions or amplifications in 47% of BN2 cases. 
Other likely gain-of-function events included 
mutations targeting cyclin D3 and CXCR5, 
whereas inactivating lesions targeting the im-
mune regulator CD70 suggested immune escape.
N1 was characterized by NOTCH1 mutations 
and aberrations targeting transcriptional regula-
tors of B-cell differentiation (IRF4, ID3, and 
BCOR), which may contribute to its plasmacytic 
phenotype (see below). TNFAIP3 mutations in 
N1 could reinforce this phenotype by fostering 
NF-κB–induced IRF4 expression.
EZB was enriched for most genetic events pre-
viously ascribed to GCB DLBCL, including BCL2 
translocation, EZH2 mutation, and REL amplifi-
cation, as well as inactivation of the tumor sup-
pressors TNFRSF14, CREBBP, EP300, and KMT2D. 
The germinal-center homing pathway involving 
S1PR2 and GNA1314 was disrupted in 38% of EZB 
cases. Janus-associated kinase–signal transducers 
and activators of transcription (JAK-STAT) sig-
naling may have been promoted in 49% of cases 
by a STAT6 mutation or amplification or by a mu-
tation or deletion targeting SOCS1, a JAK-STAT 
negative regulator. Phosphatidylinositol 3 (PI3) 
kinase–mammalian target of rapamycin signaling 
may have been activated in 23% of cases by MTOR 
mutations or amplification of MIR17HG, encod-
ing a microRNA targeting PTEN. Immune editing 
may also sculpt EZB genomes since 39% acquired 
lesions in the major histocompatibility complex 
class II pathway genes CIITA and HLA-DMA.
Epigenetic Attributes of the DLBCL Genetic 
Subtypes
We used RNA-sequencing data to explore pheno-
typic differences among the DLBCL genetic sub-
types, using gene-expression signatures of B-cell 
differentiation, oncogenic signaling, and the tu-
mor microenvironment15 (Fig. 3). MCD expressed 
genes that are transactivated by IRF4, a master 
regulator of the ABC phenotype.10 In EZB, a sig-
nature of BCL6-repressed genes was low and a 
signature of TCF3-activated genes was high, im-
plying a germinal-center origin. N1 expressed a 
plasma-cell signature highly.
Among oncogenic signatures, NOTCH signa-
tures were highest in BN2 and N1. Signatures of 
B-cell receptor–dependent NF-κB activation were 
highest in MCD and BN2. Genes induced by MYC 
were highly expressed in MCD and BN2, as were 
signatures of proliferation. Conversely, a signa-
ture of quiescent cells was high in N1.
With respect to the tumor microenvironment, 
signatures of T cells, myeloid cells, and follicu-
lar dendritic cells were highest in N1. BN2 and 
EZB cases expressed the Stromal-1 signature 
highly, which reflects a fibrotic microenviron-
Figure 3. Gene-Expression Signatures That Distinguish the DLBCL Genetic Subtypes.
The mean values of the indicated signature averages for cases assigned to each genetic subtype are shown. A full annotation of these 
signatures is available in Figure S3 in Supplementary Appendix 1 and at https:/ / lymphochip . nih . gov/ signaturedb/ . P values were calculated 
with the use of an F‑test. I bars indicate standard errors.
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ment that is associated with favorable survival in 
DLBCL after immunochemotherapy.3
Clinical Attributes of the DLBCL Genetic 
Subtypes
For the survival analysis, we selected all untreated 
patients with outcome data who received immu-
nochemotherapy (R-CHOP or CHOP-like chemo-
therapy; 240 patients), including 119 patients 
whose tumors were classified into one of the 
genetic subtypes. Our genetic algorithm, which 
did not use clinical information, was locked 
down before the analysis of clinical data, allow-
ing us to analyze the relationship between ge-
netic subtypes and survival in this entire cohort. 
The four subtypes differed significantly in pro-
gression-free survival (P = 8.88×10−6) and overall 
survival (P = 1.70×10−4), with the BN2 and EZB 
subtypes having much more favorable outcomes 
than the MCD and N1 subtypes (Fig. 4A and 4B). 
The predicted 5-year overall survival rates for the 
MCD, N1, BN2, and EZB subtypes were 26%, 
36%, 65%, and 68%, respectively.
Within ABC DLBCL, the MCD, N1, and BN2 
genetic subtypes had distinct progression-free 
survival (P = 0.006) and overall survival (P = 0.002) 
(Fig. 4C and 4D). Patients with MCD had sig-
nificantly inferior survival as compared with 
those with BN2, and patients with either MCD 
or N1 had significantly inferior survival as com-
pared with patients with ABC tumors that were 
not genetically classified (Fig. 4C and 4D). Within 
GCB DLBCL, there was a trend toward inferior 
overall survival among patients with EZB as 
compared with patients with other GCB tumors 
(P = 0.06) (Fig. 4E). The distinction regarding the 
gene-expression profiling subgroup and the dis-
tinction regarding the genetic subtype contrib-
uted independently to survival in a multivariate 
analysis: gene-expression profiling added signifi-
cantly to a genetic-subtype model (P = 7.91×10−7), 
and genetic subtype added significantly to a 
gene-expression profiling model (P = 4.16×10−4).
The IPI score did not vary significantly among 
the genetic subtypes (Tables S9 and S10 in Sup-
plementary Appendix 2). However, with respect 
to individual IPI components, patients with EZB 
tumors had significantly better performance sta-
tus (greater prevalence of an Eastern Cooperative 
Oncology Group performance status >1; P = 0.001). 
A trend toward increased extranodal involvement 
(>1 site) was a feature of MCD (28% prevalence, 
as compared with 16% in others; P = 0.051) and 
potentially N1 (38%; P = 0.06). The degree of 
extranodal involvement in MCD is of interest, 
given the frequent CD79B and MYD88L265P muta-
tions in these tumors, which are cardinal fea-
tures of extranodal lymphomas such as primary 
central nervous system lymphoma.16 Moreover, 
several other genes that were characteristically 
mutated in MCD tumors are recurrently mutated 
in primary central nervous system lymphoma 
(Fig. S4 in Supplementary Appendix 1).
The IPI score was associated with progression-
free survival (P = 1.51×10−6) and overall survival 
(P = 6.05×10−5), as expected. The genetic subtype 
distinction added significantly to the IPI model 
of progression-free survival (P =5.60×10−4) and 
overall survival (P = 0.001).
Oncogenic Pathways
To gain insight into potential therapeutic strate-
gies for the genetic subtypes of DLBCL, we con-
sidered groups of genetic aberrations that target 
oncogenic signaling pathways (Fig. 5). First, we 
considered the regulation of proximal B-cell re-
ceptor signaling, both positively by mutation or 
amplification of CD79B and CD79A (“CD79A/B”) 
and negatively by known inhibitors of B-cell re-
ceptor signaling in normal B cells, including 
LAPTM5,17 LYN,18 PTPN6,18 GRB2,19 PRKCD,20 
DGKZ,21 SLA,22 and MAP4K123 (Fig. 5, and Fig. 
S5A in Supplementary Appendix 1). Potential 
loss-of-function lesions targeting negative regu-
lators of B-cell receptor signaling (“BCRnegreg”) 
were present in 38.5% of cases. They were more 
prevalent in CD79A/B cases with MYD88L265P 
(56%) than in cases lacking these aberrations 
(36.4%) (P = 0.02). This is notable given evidence 
Figure 4 (facing page). Relationship between DLBCL 
 Genetic Subtypes and Survival after R-CHOP 
 Chemotherapy.
Panels A and B show Kaplan–Meier models of progres‑
sion‑free survival and overall survival, respectively, ac‑
cording to DLBCL genetic subtype. Panels C and D show 
Kaplan–Meier models of progression‑free survival and 
overall survival, respectively, among patients with ABC 
DLBCL according to genetic subtype and including pa‑
tients with non‑subtyped ABC cases as “other ABC.” 
Panel E shows a Kaplan–Meier model of overall survival 
among patients with GCB DLBCL cases belonging to 
the EZB subtype or not (“other GCB”). R‑CHOP denotes 
rituximab, cyclophosphamide, doxorubicin, vincristine, 
and prednisone.
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that aggressive lymphomas with both MYD88L265P
and CD79B mutations frequently have a response 
to ibrutinib and presumably have “chronic active” 
B-cell receptor signaling.4,16,24
Signaling enzymes and adaptors that pro-
mote B-cell receptor–dependent NF-κB activation 
(“BCR–NF-κB”) were genetically aberrant in 44.9% 
of cases (Fig. 5, and Fig. S5A and S5B in Supple-
Figure 5. Genetic Aberrations Targeting Oncogenic Signaling Pathways in DLBCL.
Shown is the prevalence of putative gain‑of‑function or loss‑of‑function genetic aberrations targeting genes in each indicated oncogenic 
signaling category. The prevalence of genetic aberrations is indicated by the color scale shown. Genetic aberrations included for each gene 
are indicated in Figure S5B in Supplementary Appendix 1. BCR denotes B‑cell receptor, CBM complex CARD11–BCL10–MALT1 signaling 
adaptor complex, mRNA messenger RNA, and NF‑κB nuclear factor κB.
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mentary Appendix 1). This B-cell receptor signal-
ing cascade activates IκB kinase (IKK), which was 
altered in 8.5% of cases. IKK is negatively regu-
lated by A20 and its partner TNIP1, which were 
targeted by mutations and deletions in 25.8% of 
cases. A variety of additional genetic events in 
66.2% of cases affected other NF-κB regulators, 
such as TLR2 and regnase-1 (ZC3H12A), which 
negatively regulates the stability of NF-κB– 
dependent messenger RNA (mRNA).25 The PI3 
kinase pathway, which can indirectly activate 
NF-κB,26 was genetically altered in 34.3% of cases.
Among the genetic subtypes, BCRnegreg aber-
rations were most frequent in MCD and least 
frequent in EZB, but these aberrations occurred 
in all genetic subtypes, suggesting that constitu-
tive B-cell receptor signaling is a pervasive as-
pect of DLBCL pathogenesis (Fig. S5B in Supple-
mentary Appendix 1). In addition to BCRnegreg 
alterations, MCD frequently acquired CD79A/B 
aberrations and thus was significantly enriched 
for lesions targeting B-cell receptor proximal 
signaling (in 75% of cases; P = 3.72×10−6). BN2 
was notably enriched for BCR–NF-κB aberrations 
(in 66% of cases; P = 3.81×10−6) and IKK regula-
tor aberrations (in 56% of cases; P = 8.34×10−11). 
These findings support the hypothesis that B-cell 
receptor–dependent NF-κB activation is a recur-
rent feature of MCD and BN2 tumors.
In addition to NF-κB, survival of DLBCL cells 
is promoted by antiapoptotic BCL2 family mem-
bers (BCL2, BCL-XL [BCL2L1], and MCL1), which 
were targeted by genomic amplification or trans-
location in 17.4% of cases (Fig. 5, and Fig. S5A 
and S5B in Supplementary Appendix 1). As ex-
pected, BCL2 mRNA levels were significantly 
higher in EZB tumors with BCL2 translocations 
than in other EZB tumors (P = 0.004) (Fig. S5C in 
Supplementary Appendix 1). MCD tumors also 
had high BCL2 mRNA expression as compared 
with other cases (P = 0.009) (Fig. S5C in Supple-
mentary Appendix 1), a finding that potentially 
explains why MCD was significantly lacking in 
amplifications and translocations of antiapop-
totic BCL2 family members (P = 1.60×10−4) (Fig. 
S5A in Supplementary Appendix 1).
Discussion
The genetic framework for DLBCL that we pres-
ent here provides a new and evolving under-
standing of the pathogenesis of DLBCL and the 
molecular attributes that may influence therapeu-
tic response. Unlike previous genetic investiga-
tions that catalogued individual genetic aberra-
tions, our study identified genetic subtypes of 
DLBCL that differ from one another by many 
recurrent genetic aberrations. There are two over-
arching implications of these findings. First, it 
seems likely that these genetic subtypes have 
distinct evolutionary histories driven by the stage 
of B-cell differentiation from which they arise or 
by their initiating genetic events (or both), which 
may influence the subsequent acquisition of co-
operating genetic lesions. Second, the genetic 
subtypes had distinct outcomes after immuno-
chemotherapy and could affect the selection of 
targeted therapies owing to their distinct onco-
genic abnormalities.
The MCD genetic subtype was enriched for 
many of the genetic changes that have been as-
cribed previously to the ABC subgroup of DLBCL. 
MCD included cases with both MYD88L265P and 
CD79B mutations, a genotype that has been as-
sociated with a response to ibrutinib in relapsed 
or refractory ABC DLBCL4 and is common in pri-
mary central nervous system lymphoma, which 
has an ABC phenotype and which often has a 
response to ibrutinib.16,24 Moreover, MCD tumors 
had extensive extranodal involvement and ac-
quired mutations in genes that are recurrently 
mutated in primary extranodal lymphomas. To-
gether, these observations suggest that the patho-
genesis of nodal MCD DLBCL is related to that 
of primary extranodal lymphomas.
The BN2 subtype sheds light on unclassified 
DLBCL, a previously obscure gene-expression sub-
group, and is predicted to rely on B-cell receptor–
dependent NF-κB activation and to be responsive 
to antagonists of B-cell receptor signaling such 
as the Bruton’s tyrosine kinase (BTK) inhibitors. 
NOTCH2 mutations link BN2 to marginal-zone 
lymphoma, which is also responsive to ibruti-
nib.27-29 BCL6 fusions, the second defining fea-
ture of BN2, are common in transformed mar-
ginal-zone lymphoma,30 raising the possibility 
that BN2 arises from an occult marginal-zone 
lymphoma. N1 differs from BN2 genetically, 
phenotypically, and clinically, despite functional 
similarities between NOTCH1 and NOTCH2, 
suggesting a distinct pathogenesis. Finally, most 
of the genetic lesions previously associated 
with GCB DLBCL were concentrated in the EZB 
subtype, ref lecting a shared genetic pathogen-
esis and distinguishing them from other GCB 
tumors.
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In our cohort, these genetic subtypes differed 
in their outcomes after immunochemotherapy, 
which were favorable in BN2 and EZB and 
poorer in MCD and N1. Moreover, within ABC 
DLBCL, heterogeneity in clinical outcome can be 
traced, in part, to genetic heterogeneity, with 
inferior survival in the MCD and N1 subtypes and 
favorable survival in the BN2 subtype. Hence, our 
findings suggest that clinical trials involving pa-
tients with ABC DLBCL who received R-CHOP–
like chemotherapy should be interpreted in the 
light of these genetic distinctions. Our survival 
analysis tested a single hypothesis on the basis 
of a locked-down genetic-subtype algorithm that 
did not use the clinical data. Nonetheless, evalu-
ation of the relationship between these genetic 
subtypes and treatment response in additional 
cohorts will be important to confirm and extend 
these findings.
The results of our studies suggest that, in 
clinical trials, targeted agents in DLBCL could 
be evaluated in the context of particular genetic 
subtypes or genetic aberrations that affect the 
targeted pathway. For example, drugs that target 
B-cell receptor–dependent NF-κB activation (e.g., 
inhibitors of BTK and protein kinase C beta) 
could be investigated in BN2 and MCD, given 
their enrichment for genetic aberrations that 
should activate or augment this signaling. Clini-
cal trials evaluating inhibitors of B-cell receptor 
proximal signaling (e.g., spleen tyrosine kinase 
[SYK] inhibitors) or the downstream PI3 kinase 
pathway could investigate whether response is 
correlated with lesions that alter negative regula-
tors of B-cell receptor signaling or the B-cell 
receptor subunits CD79A and CD79B. Differen-
tial BCL2 expression could be considered in the 
assessment of response to BCL2 inhibitors. Fi-
nally, immune-checkpoint inhibitors could be 
studied in the N1 subtype, given its prominent 
T-cell gene-expression signature and poor re-
sponse to R-CHOP.
In summary, our multiplatform genomic analy-
sis builds on the gene-expression classification 
of DLBCL by the addition of a genetic nosology 
that may inform DLBCL pathogenesis. Our analy-
sis uncovered an interrelationship between this 
genetic nosology and oncogenic signaling path-
ways, suggesting testable therapeutic interven-
tions. From the perspective of precision medi-
cine, selecting treatment for DLBCL on the basis 
of individual genetic alterations is not optimal 
since it is likely that constellations of genetic 
aberrations influence therapeutic response. The 
genetic subtypes that we define may provide a 
conceptual edifice on which to develop precision 
therapies for these aggressive cancers.
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